Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

Takuji Okusaka(National Cancer Center), Y Nimura(Aichi Cancer Center), Soshi Nagaoka(Eli Lilly (Japan)), A Funakoshi(National Hospital Organization Kyushu Cancer Center), Junji Furuse(Kyorin University), Nobumasa Mizuno(Aichi Cancer Center), Yoshihiro Nambu(Eli Lilly (Japan)), Akira Fukutomi(Shizuoka Cancer Center), Jumpei Funai(Eli Lilly (Japan)), Masaru Miyazaki(Chiba University), Masato Nagino, Satoshi Kondo(Hokkaido University), S. Ohkawa(Kanagawa Prefectural Hospital Organization), Minori Koshiji(Eli Lilly (Japan)), Kohei Nakachi(National Cancer Center Hospital East)
British Journal of Cancer
July 13, 2010
10.1038/sj.bjc.6605779
Cited by 749

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977